NeOnc Technologies Boosts Drug Discovery with AI and 3D Bioprinting IP Acquisition

CALABASAS, Calif. — August 25, 2025 — Leads & Copy — NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) has acquired an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. The move will fortify NeOnc’s drug discovery engine and accelerate its mission to develop therapies for complex neurological cancers.

The newly acquired IP includes U.S. Patent No. 11,788,057 B2, and allows NeOnc to create patient-derived 3D brain tumor models. The company can perform high-throughput screening of therapeutic candidates with speed and accuracy by applying AI and quantum modeling algorithms to biological environments. The technology will de-risk and shorten the preclinical development timeline.

The transaction was valued at $3.5 million, consisting of $500,000 in cash and $3 million in NeOnc common stock at $25 per share. The technology will support its strategic partnership with Quazar Investment Group to advance clinical trials across the GCC region.

Dr. Ishwar K. Puri, Senior Vice President of Research and Innovation at the University of Southern California (USC), has joined NeOnc’s Board of Directors.

Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, said that finalizing the acquisition is a transformative milestone for NeOnc, equipping it with technology that complements its clinical-stage assets. Dr. Puri said that uniting cutting-edge computational science with NeOnc’s targeted therapeutic pipeline can build a new paradigm in precision oncology.

NeOnc Technologies Holdings, Inc. is focused on the development and commercialization of central nervous system therapeutics designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038.

Company Contact:
info@neonc.com 

Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com

Source: NeOnc Technologies Holdings, Inc.

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.